SEP 10, 2020
Academy, Ophthalmic Community Challenge FDA Plan, Ensure Access to Compounded Moxifloxacin
The Academy recommends that the U.S. Food and Drug Administration retain moxifloxacin on the bulk substance list, ensuring continued access to compounded moxifloxacin for our patients.